GSK beat third-quarter sales and profit forecasts on Thursday, powered by strong demand for its newer specialty medicines. The British drugmaker reported revenue of £8.89 billion for the three months ended September 30, up 5% at constant-currency rates, and core earnings of 54.6 pence per share. Both figures came in ahead of analyst expectations, which had called for revenue of £8.84 billion and earnings of 50.4 pence per share.
The results mark an early checkpoint for CEO Luke Miels, who took the helm at the start of 2026 and is overseeing what Reuters described as GSK's biggest shake-up in years. The company is trying to offset looming patent expirations on some of its older blockbuster drugs by pivoting toward newer treatments in areas like respiratory disease, HIV and oncology.
New drugs drive growth, but costs rise
The revenue growth was led by GSK's newer specialty medicines, which have been gaining market share and helping to cushion the impact of generic competition on older products. Investors have been watching closely to see whether these new drugs can generate enough sales to replace the revenue that will be lost when key patents expire.
However, the company also flagged that research and development (R&D) spending is growing faster than sales. That is a common pattern for large pharmaceutical companies as they invest heavily in late-stage clinical trials and early-stage research to fill their pipelines. But it can weigh on profit margins in the near term, and GSK's decision to highlight it suggests investors should expect continued pressure on costs.
In addition, GSK booked a £328 million charge related to a savings-drive program. Such charges typically cover restructuring costs, severance payments and other one-off expenses tied to efficiency initiatives. While they reduce reported profit in the quarter, they are often seen as a sign that management is taking steps to improve long-term profitability.
Annual targets held steady
Despite the higher costs, GSK kept its full-year targets unchanged. That will reassure investors who might have worried that the savings-drive charge or rising R&D spending would force the company to trim its guidance. Maintaining guidance is often seen as a signal that management is confident in the underlying momentum of the business.
The company's ability to beat forecasts while absorbing a significant charge is a positive sign, but it also highlights the balancing act facing Miels. He must fund the research needed to sustain long-term growth while also delivering the short-term results that keep shareholders happy.
What it means for investors
For everyday investors, GSK's results offer a few takeaways. First, the beat shows that the company's strategy of focusing on specialty medicines is starting to pay off, at least in terms of sales growth. Second, the rising R&D spending and the savings-drive charge are reminders that pharmaceutical companies often face volatile costs as they invest in future products and restructure their operations.
Investors should also keep an eye on the patent cliff. When a major drug loses patent protection, sales can drop sharply as cheaper generics enter the market. GSK's ability to offset that with new products will be a key driver of its share price over the next few years.
The broader market context is also relevant. GSK is not the only company navigating these challenges. Across the pharmaceutical sector, firms are grappling with similar pressures, and investors are increasingly focused on pipeline strength and cost discipline. For a look at how other companies are handling their own cost pressures, see our coverage of Symrise's warning on margins.
GSK's results also come at a time when investors are paying close attention to earnings beats and guidance across industries. As seen with Standard Chartered's raised targets, companies that can deliver on their promises are often rewarded by the market.
Looking ahead, investors will likely watch for updates on GSK's pipeline, any further details on the savings program, and whether the company can maintain its growth trajectory in the face of rising costs. The next few quarters will be crucial in determining whether Miels' shake-up is delivering the results he promised.
